Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NVRO - Nevro Corp


Close
6.19
-0.150   -2.423%

Share volume: 925,112
Last Updated: Fri 30 Aug 2024 10:00:03 PM CEST
Surgical and Medical Instrument Manufacturing : -0.56%

PREVIOUS CLOSE
CHG
CHG%

$6.34
-0.15
-2.37%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
19%
Profitability 12%
Dept financing 24%
Liquidity 75%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
6.72%
1 Month
-36.51%
3 Months
-32.50%
6 Months
-58.23%
1 Year
-69.36%
2 Year
-86.46%
Key data
Stock price
$6.19
P/E Ratio 
-2.98
DAY RANGE
$6.16 - $6.49
EPS 
-$2.12
52 WEEK RANGE
$4.38 - $22.64
52 WEEK CHANGE
-$0.70
MARKET CAP 
230.783 M
YIELD 
N/A
SHARES OUTSTANDING 
37.283 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
2.15
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$578,901
AVERAGE 30 VOLUME 
$995,066
Company detail
CEO: D.Keith Grossman
Region: US
Website: https://www.nevro.com
Employees: 1,218
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.

Recent news